41.98
price down icon1.51%   -0.675
 
loading

Perché le azioni Exelixis Inc (EXEL) sono in ribasso?

Abbiamo notato un calo di 12.00% nelle azioni di Exelixis Inc (EXEL) durante la sessione di negoziazione di 2025-10-20. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-10-23:

Shares of Exelixis, Inc. (EXEL) dropped by 8.81% from $21.11 to $19.25 in the trading on Monday, October 23, 2023. The reason why EXEL stock down is due to the company's announcement on detailed results from its Phase 3 CABINET pivotal evaluating Cabozantinib in advanced neuroendocrine tumors:

  • The CABINET trial achieved its primary objective, showing significant improvements in median progression-free survival (PFS) for patients with advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET).
  • The trial was halted early due to the remarkable efficacy observed during an interim analysis, with consistent safety profiles.
  • Exelixis plans to discuss these findings with the FDA to potentially offer a new treatment option for patients with these challenging cancers. Investors' cautious response to this news led to the decline in Exelixis, Inc.'s stock price.
$70.31
price down icon 0.40%
$20.16
price down icon 1.68%
$37.96
price down icon 3.85%
$30.44
price up icon 0.31%
$101.64
price down icon 0.87%
$703.57
price down icon 2.97%
Capitalizzazione:     |  Volume (24 ore):